Sign In
Buy GLP
$49.26
+1.26 (+2.63%)
At Close: Jun 02, 2026
GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain
03:31pm, Tuesday, 19'th May 2026
Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.
1Q26 MLP/Midstream Dividends: Growth Trend Continues
07:06am, Tuesday, 19'th May 2026
Key Takeaways: On a year-over-year basis, 96.0% of the Alerian Midstream Energy Index (AMNA) by weighting have grown their dividends. MLPs largely drove sequential growth in payouts for 1Q26, while mo
Are Investors Undervaluing Global Partners (GLP) Right Now?
10:40am, Monday, 18'th May 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Vancouver, Canada, May 18, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development
Hims & Hers Health: GLP-1 Drama Ending Signals Return To Growth
02:00pm, Sunday, 17'th May 2026
Hims & Hers Health has returned to growth mode after volatility from the GLP-1 transition, yet trades near multi-year lows. The online health platform guided up 2026 revenues to $3B, exceeding consens
As millions flock to GLP-1s, doctors warn of a rise in frailty caused by rapid muscle wasting
12:00pm, Sunday, 17'th May 2026
Losing muscle, as well as fat, is an unexpected downside of the popular drugs that isn't broadly discussed or immediately apparent.
Analysts say this restaurant chain has figured out how to feed everyone — GLP-1 users included
01:34pm, Thursday, 14'th May 2026
J.P. Morgan upgraded Cheesecake Factory's stock, as weight-loss drugs and cautious consumers make the restaurant industry more anxious.
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?
11:20am, Thursday, 14'th May 2026
NVO beats Q1 estimates and raises its 2026 outlook. Meanwhile, Eli Lilly's expanding GLP-1 portfolio threatens its obesity market dominance.
Global Partners (GLP) is an Incredible Growth Stock: 3 Reasons Why
01:46pm, Wednesday, 13'th May 2026
Global Partners (GLP) possesses solid growth attributes, which could help it handily outperform the market.
- VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager's continued innovation in gene therapy - LEXINGTON, Mas
Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?
01:00pm, Tuesday, 12'th May 2026
Shares of telehealth provider Hims & Hers Health NYSE: HIMS sold off sharply following disappointing Q1 FY2026 financial results, with shares falling more than 12% in after-hours trading after the com
GLP-1 Wars: Winners & Losers
12:56pm, Tuesday, 12'th May 2026
With its best-in-breed GLP-1 drugs, Eli Lilly is beginning to cement itself as the dominant player in the massive GLP-1 market.
Hims & Hers tumbles 15% after earnings miss as GLP-1 transition weighs on results
07:48am, Tuesday, 12'th May 2026
Shares of Hims & Hers Health (HIMS) fell sharply in premarket trading on Tuesday after the telehealth company reported weaker-than-expected first-quarter revenue and a surprise loss. The stock dropped
Novo Nordisk GLP-1 pill launch impresses but price erosion keeps Citi on the sidelines
09:23am, Monday, 11'th May 2026
Shares in Novo Nordisk (NYSE:NVO) drew a cautious reception from Citi following first-quarter results that beat consensus expectations, with the bank raising its target price but retaining a neutral r
CAMBRIDGE, Mass., May 11, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that a late-breakin
